Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
July 08 2024 - 8:36AM
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage
biotechnology company developing novel molecular glue degrader
(MGD)-based medicines, today announced that Markus Warmuth, M.D.,
Chief Executive Officer, will participate in a fireside chat at the
virtual UBS Targeted Protein Degradation Day on Monday, July 15,
2024, at 3:30 p.m. ET.
A webcast of the presentation will be accessible via the “Events
& Presentations” section of Monte Rosa’s website at
ir.monterosatx.com, and an archived version will be made available
for 30 days following the presentation.
About Monte RosaMonte Rosa
Therapeutics is a clinical-stage biotechnology company developing
highly selective molecular glue degrader (MGD) medicines for
patients living with serious diseases in the areas of oncology,
autoimmune and inflammatory diseases, and more. MGDs are small
molecule protein degraders that have the potential to treat many
diseases that other modalities, including other degraders, cannot.
Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of
Neosubstrates) discovery engine combines AI-guided chemistry,
diverse chemical libraries, structural biology and proteomics to
identify degradable protein targets and rationally design MGDs with
unprecedented selectivity. The QuEEN discovery engine enables
access to a wide-ranging and differentiated target space of
well-validated biology across multiple therapeutic areas. Monte
Rosa has developed the industry’s leading pipeline of MGDs, which
spans oncology, autoimmune and inflammatory disease and beyond, and
has a strategic collaboration with Roche to discover and develop
MGDs against targets in cancer and neurological diseases previously
considered impossible to drug. For more information, visit
www.monterosatx.com.
InvestorsAndrew Funderburk
ir@monterosatx.com
MediaCory Tromblee, Scient
PRmedia@monterosatx.com
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Monte Rosa Therapeutics (NASDAQ:GLUE)
Historical Stock Chart
From Oct 2023 to Oct 2024